Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy

Fumio Kanda, Kenji Sekiguchi, Kenichi Oishi, Hirotoshi Hamaguchi, Shigeru Mitsui, Hiroshi Kobessho, Masatsugu Higuchi, Toshihiko Shirafuji, Hiroyuki Ishihara

Research output: Contribution to journalArticlepeer-review

Abstract

The intravenous immunoglobulin infusion therapy (IVIg) has recently acquired an important role in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Some patients, however, require repetitive infusions to maintain the improvement. We planned a one-day therapy with 0.4 g/kg of IVIg in every 7 or 10 days for two CIDP patients who had required a 5-day course of IVIg in every month because of frequent exacerbations. Serum levels of IgG in both patients were kept as high as 2,000 mg/dl resulting in maintaining the improvement without any side effects.

Original languageEnglish (US)
Pages (from-to)236-238
Number of pages3
JournalClinical Neurology
Volume46
Issue number3
StatePublished - Mar 2006
Externally publishedYes

Keywords

  • CIDP
  • Hyperviscosity syndrome
  • IVIg

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy'. Together they form a unique fingerprint.

Cite this